Navigation Links
Genetic Technologies Processes First BREVAGen™ Patient Sample

VICTORIA, Australia, May 31, 2011 /PRNewswire/ -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) has received and processed its first BREVAGen clinical sample from a US patient.  This follows last month's receipt of certification of its Australian laboratory under the US Clinical Laboratories Improvements Amendments (CLIA) (42 U.S.C. 263a).

The sample was received by Phenogen Sciences, the Company's new North American subsidiary, where the cheek swab sample was bar-coded and entered into the Laboratory Information Management System, before being priority shipped to Australia for processing.  Subsequently the results were made electronically accessible to the Company's North Carolina offices for immediate distribution to the requesting physician.  All systems functioned as expected and no infrastructure hurdles remain to full market availability.

The results enabled the patient's physician to better understand the personalized risk of non-familial breast cancer, allowing better management and prevention of disease.  The patient is one of an estimated 1.3 million new patients annually in the US who could benefit from such a test.

"64 percent of the target patient population will have their breast cancer risk re-classified as a result of using the BREVAGen test, providing a more personalized and actionable assessment.  Many women will have their peace of mind improved by being re-classified to a lower risk group while for others, they will be re-classified to a higher risk group, enabling decisions regarding increased surveillance or even cancer preventive therapy," said Mr. Lewis Stuart, Phenogen Sciences President and General Manager.

Concurrently, Phenogen Sciences has now hired its initial sales team in preparation for the imminent launch of BREVAGen.  Now at their inaugural sales symposium, the sales team has been reviewing all available literature, technical details and benefits of the test.  This has involved Company experts, external medical faculty and key opinion leaders.  Speakers are part of a more extensive Key Opinion Leader network the company has been building over the last 12 months.  Located in leading oncology institutions, this network of practicing physicians and academics will be utilized to strongly position and support the launch of BREVAGen and build the Company's sales.

About BREVAGen™The BREVAGen™ breast cancer risk stratification test is a novel genetic test panel that examines a patient's buccal (cheek) swab to detect the absence or presence of certain common genetic variations (SNPs) associated with an increased risk for developing breast cancer. The test is designed to help physicians assess aggregate breast cancer risk from these genetic markers, together with factors from a standard clinical assessment based on a patient's family and personal history. These factors combine to give a clearer picture of an individual woman's risk of developing breast cancer. The BREVAGen™ test may be especially useful for women at intermediate risk of developing breast cancer, including those who have undergone breast biopsies. The test will provide information that can help physicians recommend alternative courses of action, such as more vigilant, targeted surveillance or preventive therapy, on a personalized patient-by-patient basis.

About Genetic Technologies LimitedGenetic Technologies was an early pioneer in recognizing important new applications for "non-coding" DNA (Deoxyribonucleic Acid).  The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all species.  Its business strategy is the global commercialization of its patents through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics portfolio.  Genetic Technologies is an ASX and NASDAQ listed company with operations in the USA and Australia. For more information, please visit

Safe Harbor StatementAny statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.FOR FURTHER INFORMATION PLEASE CONTACTDr Paul D R MacLeman

Rudi Michelson (Australia)

Seth Lewis (USA)Chief Executive Officer

Monsoon Communications

Trout Group Inc.Genetic Technologies Limited

+61 3 9620 3333

+1 646 378 2952Phone: +61 3 8412 7000

SOURCE Genetic Technologies Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Signal Genetics Announces Commercialization Partnership with NeoGenomics Laboratories for Multiple Myeloma Gene Expression Test
2. USP Hospitales of Spain to Offer Interleukin Genetics Heart Health Test Throughout Its Hospital Network
3. Medco Research Institute® and AssureRx Health Initiate Pilot Program to Evaluate Adoption and Clinical Impact of Pharmacogenetic Testing for Selection of Psychotropic Medications
4. Life Technologies Launches 7500 Fast Dx Real-Time PCR Instrument and 3500 Dx Series Genetic Analyzer in Japan
5. Interleukin Genetics and Metagenics Initiate Research Collaboration
6. Technology Collaboration Between New England Biolabs and Sequenom Delivers First Product for Epigenetics
7. Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer
8. LABS, Inc. Announces Alliance with Ambry Genetics to Expand Testing Solutions for the Reproductive Health Industry
9. RainDance Technologies and Ambry Genetics Expand Collaboration to Address ADME Analysis
10. JS Genetics Develops New Non-Invasive Test, XCAT-TS, to Help Doctors Diagnose Turner Syndrome
11. WARFARIN Study Launched to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin
Post Your Comments:
(Date:10/13/2015)... , October 13, 2015 ... World Thrombosis Day Interactive Infographic   --> ... World Thrombosis Day  to promote vital global awareness ... and symptoms. Thrombosis is the formation of potentially ... - resulting in venous thromboembolism (VTE) - or the ...
(Date:10/12/2015)... Given the intricacy of the anatomy and physiology of ... drug effectively to a specific ocular site. Several barriers have ... include dilution of a drug by tears, clearance of a ... issues with respect to the cornea, sclera and choroid. Approximately ... due to the aforementioned barriers. --> Given ...
(Date:10/12/2015)... 12, 2015  The Pharmacy Compounding Accreditation Board ... Pharmacy in Costa Mesa , ... the pharmacy,s commitment to meeting and/or exceeding national ... --> --> ... --> --> Harbor Compounding ...
Breaking Medicine Technology:
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Scientists in ... tissue biopsy in 18 patients with or without mesothelioma. Surviving Mesothelioma has just posted ... , The doctors from PhenoPath Laboratories in Seattle and the University of British Columbia ...
(Date:10/13/2015)... ... , ... Tempe Dental Care, a leading Tempe dentists’ office, celebrates offering gentle, ... for more than 5 years. A leading cause of emergency room visits, school ... is not timely. , Sedation dentistry provides an anxiety-free dental experience ...
(Date:10/13/2015)... ... , ... Local Gold’s Gym franchise owner, Bryce Berry, received the Visionary of ... owns and operates Gold's Gym Cheyenne in Cheyenne, Wyoming, received the award ... States. A brand leader in global fitness, Gold’s Gyms are located worldwide. Every fitness ...
(Date:10/13/2015)... ... October 13, 2015 , ... Thermi, an ... newest professional to introduce the latest development, ThermiVa® temperature controlled radiofrequency to the ... professional in Obstetrics and Gynecology and a pioneer in the field of laparoscopy. ...
(Date:10/13/2015)... ... October 13, 2015 , ... In an ongoing effort ... , a Southlake, Texas, child development and pediatric therapy center, is working with ... families about their options for receiving this kind of care for affected children. ...
Breaking Medicine News(10 mins):